These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37963441)

  • 1. Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study.
    Lan L; Lin Y; Yu B; Wang Y; Pan H; Wang H; Lou X; Lang X; Zhang Q; Jin L; Yang Y; Xiao L; Chen J; Han F
    Am J Nephrol; 2024; 55(1):25-36. PubMed ID: 37963441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases.
    Kronbichler A; König P; Busch M; Wolf G; Mayer G; Rudnicki M
    Wien Klin Wochenschr; 2013 Jun; 125(11-12):328-33. PubMed ID: 23624956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idiopathic nephrotic syndrome in Syrian children: clinicopathological spectrum, treatment, and outcomes.
    Wannous H
    Pediatr Nephrol; 2024 Aug; 39(8):2413-2422. PubMed ID: 38587559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis.
    Hansrivijit P; Cheungpasitporn W; Thongprayoon C; Ghahramani N
    BMC Nephrol; 2020 Apr; 21(1):134. PubMed ID: 32293308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of cyclosporine A in adult nephrotic syndrome with minimal change disease and focal-segmental glomerulosclerosis: a multicenter study in Korea.
    Lee HY; Kim HS; Kang CM; Kim SG; Kim MJ
    Clin Nephrol; 1995 Jun; 43(6):375-81. PubMed ID: 7554521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy.
    Ramachandran R; Bharati J; Rao I; Kashif AW; Nada R; Minz R; Gupta KL; Kohli HS
    Nephrology (Carlton); 2019 Dec; 24(12):1241-1247. PubMed ID: 30586217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic efficacy of rituximab for the management of adult-onset steroid-dependent nephrotic syndrome: a retrospective study.
    Katsuno T; Masuda T; Saito S; Kato N; Ishimoto T; Kato S; Kosugi T; Tsuboi N; Kitamura H; Tsuzuki T; Ito Y; Maruyama S
    Clin Exp Nephrol; 2019 Feb; 23(2):207-214. PubMed ID: 30121802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome.
    Ruggenenti P; Ruggiero B; Cravedi P; Vivarelli M; Massella L; Marasà M; Chianca A; Rubis N; Ene-Iordache B; Rudnicki M; Pollastro RM; Capasso G; Pisani A; Pennesi M; Emma F; Remuzzi G;
    J Am Soc Nephrol; 2014 Apr; 25(4):850-63. PubMed ID: 24480824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab treatment for refractory nephrotic syndrome in adults: a multicenter retrospective study.
    Ma X; Fang L; Sheng L; Zhou X; Bai S; Zang X; Wang Y; Li M; Lv Z; Zhong Q; Yang X; Wang Y; Hu Y; Yan D; Shi Y; Chen H; Li J; Tao M; Zhuang S; Wang Y; Liu N
    Ren Fail; 2023 Dec; 45(1):2237124. PubMed ID: 37482915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review.
    Kronbichler A; Kerschbaum J; Fernandez-Fresnedo G; Hoxha E; Kurschat CE; Busch M; Bruchfeld A; Mayer G; Rudnicki M
    Am J Nephrol; 2014; 39(4):322-30. PubMed ID: 24751753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of Rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING).
    C Willcocks L; Qian W; Cader R; Gatley K; Siddiqui H; Tabebisong E; Champion K; Kronbichler A; Lightstone L; Jayne D; Wilson E; Griffith M
    BMC Nephrol; 2024 Aug; 25(1):253. PubMed ID: 39112932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging therapeutic strategies for minimal change disease and focal and segmental glomerulosclerosis.
    Siligato R; Cernaro V; Nardi C; De Gregorio F; Gembillo G; Costantino G; Conti G; Buemi M; Santoro D
    Expert Opin Investig Drugs; 2018 Nov; 27(11):839-879. PubMed ID: 30360670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of low-dose rituximab in minimal change disease and prevention of relapse.
    Zhang J; Zhao H; Li X; Qian R; Gao P; Lu S; Ma Z
    BMC Nephrol; 2023 Apr; 24(1):112. PubMed ID: 37101300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obinutuzumab May Be an Effective and Safe Option for Adult Minimal Change Disease and Focal Segmental Glomerulosclerosis Patients after Multitarget Therapy Including Rituximab.
    Lin Y; Pan Y; Han Q; Xu J; Wang J; Lei X; Chen L; Wang Y; Ren P; Lan L; Chen J; Han F
    Am J Nephrol; 2024 Oct; ():1-10. PubMed ID: 39396511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to remission of proteinuria and incidence of relapse in patients with steroid-sensitive minimal change disease and focal segmental glomerulosclerosis: the Japan Nephrotic Syndrome Cohort Study.
    Yamamoto R; Imai E; Maruyama S; Yokoyama H; Sugiyama H; Takeda A; Tsukamoto T; Uchida S; Tsuruya K; Shoji T; Hayashi H; Akai Y; Fukunaga M; Konta T; Nishio S; Goto S; Tamai H; Nagai K; Katafuchi R; Masutani K; Wada T; Nishino T; Shirasaki A; Sobajima H; Nitta K; Yamagata K; Kazama JJ; Hiromura K; Yasuda H; Mizutani M; Akahori T; Naruse T; Hiramatsu T; Morozumi K; Mimura T; Saka Y; Ishimura E; Hasegawa H; Ichikawa D; Shigematsu T; Sato H; Narita I; Isaka Y;
    J Nephrol; 2022 May; 35(4):1135-1144. PubMed ID: 35366214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS.
    Osterholt T; Todorova P; Kühne L; Ehren R; Weber LT; Grundmann F; Benzing T; Brinkkötter PT; Völker LA
    Sci Rep; 2023 Apr; 13(1):6980. PubMed ID: 37117201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS).
    Yamamoto R; Imai E; Maruyama S; Yokoyama H; Sugiyama H; Nitta K; Tsukamoto T; Uchida S; Takeda A; Sato T; Wada T; Hayashi H; Akai Y; Fukunaga M; Tsuruya K; Masutani K; Konta T; Shoji T; Hiramatsu T; Goto S; Tamai H; Nishio S; Shirasaki A; Nagai K; Yamagata K; Hasegawa H; Yasuda H; Ichida S; Naruse T; Nishino T; Sobajima H; Tanaka S; Akahori T; Ito T; Terada Y; Katafuchi R; Fujimoto S; Okada H; Ishimura E; Kazama JJ; Hiromura K; Mimura T; Suzuki S; Saka Y; Sofue T; Suzuki Y; Shibagaki Y; Kitagawa K; Morozumi K; Fujita Y; Mizutani M; Shigematsu T; Kashihara N; Sato H; Matsuo S; Narita I; Isaka Y
    Clin Exp Nephrol; 2020 Jun; 24(6):526-540. PubMed ID: 32146646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab in maintaining remission in adults with podocytopathy.
    Ramachandran R; Bharati J; Nada R; Minz R; Kohli HS
    Nephrology (Carlton); 2020 Aug; 25(8):616-624. PubMed ID: 32297386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?
    Gauckler P; Shin JI; Alberici F; Audard V; Bruchfeld A; Busch M; Cheung CK; Crnogorac M; Delbarba E; Eller K; Faguer S; Galesic K; Griffin S; Hrušková Z; Jeyabalan A; Karras A; King C; Kohli HS; Maas R; Mayer G; Moiseev S; Muto M; Odler B; Pepper RJ; Quintana LF; Radhakrishnan J; Ramachandran R; Salama AD; Segelmark M; Tesař V; Wetzels J; Willcocks L; Windpessl M; Zand L; Zonozi R; Kronbichler A;
    Autoimmun Rev; 2020 Nov; 19(11):102671. PubMed ID: 32942039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consolidation Treatment and Long-Term Prognosis of Rituximab in Minimal Change Disease and Focal Segmental Glomerular Sclerosis.
    Lin L; Wang W; Wu Y; Xie J; Li X; Pan X; Zhang W; Xu J; Cai Y; Ren H; Chen N
    Drug Des Devel Ther; 2021; 15():1945-1953. PubMed ID: 34007154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.